1 min read
SCOPE: Powering the Future of Clinical Research
Meet Veristat at SCOPE: Powering the Future of Clinical Research February 2-5, 2026
🔬 Advancing Clinical Research with...
2 min read
Developing therapies for neurological diseases represents one of the most challenging frontiers in modern biotechnology. With subjective clinical assessments, high variability in outcomes, and substantial investment requirements, neurology programs face unique complexities that can derail even the most promising assets.
The Investigational New Drug (IND) submission stands as a pivotal moment: not just determining whether your therapy advances to first-in-human studies, but setting the trajectory for your entire development pathway. Yet this critical inflection point is where many programs stumble, encountering delays, data gaps, or clinical holds that erode both resources and investor confidence.
The Strategic Value of Proactive Regulatory Alignment
Based on Veristat's experience across 200+ neurology and psychiatry programs in the past five years, one factor consistently separates successful INDs from those facing obstacles: early, strategic FDA engagement. The optimal window? Six to nine months before your planned IND submission.
This timing allows you to:
-
Gain FDA concurrence on study design and endpoints before major investments
-
Address potential issues while you still have flexibility to adapt
-
Demonstrate regulatory sophistication to investors and partners
-
Build a collaborative relationship with your reviewing division
Understanding Neurology-Specific IND Risks
Neurology programs face distinct challenges that require specialized attention:
Endpoints & Clinical Scales: Subjective measures and inter-rater variability can obscure treatment effects, potentially leading to inconclusive results.
Preclinical Data Relevance: Animal models may not adequately replicate human neurological disease, potentially leading to FDA requests for additional studies.
Study Population Selection: Heterogeneous disease stages and comorbidities can muddy efficacy signals and increase dropout rates.
CNS-Specific Safety Monitoring: Neurological adverse events require sophisticated monitoring approaches that satisfy regulatory expectations.
Building Your Pre-IND Success Framework
Effective pre-IND meetings require more than regulatory knowledge—they demand integrated expertise across multiple disciplines. Your preparation should include:
-
Cross-functional team alignment spanning regulatory, nonclinical, biostatistics, medical writing, and clinical operations
-
Clear development questions that elicit actionable FDA guidance
-
Focused briefing packages that demonstrate scientific rigor without overwhelming reviewers
The difference between asking "What endpoints does FDA prefer?" versus "Does FDA agree that this specific patient-reported outcome measure is appropriate as a secondary endpoint?" can determine whether you receive generic guidance or actionable direction.
Real-World Success Stories
Consider these examples from Veristat's portfolio:
-
A biopharma sponsor turned SPA rejection into BLA submission success through strategic re-engagement and advanced statistical approaches
-
A small biotech secured both FDA and EMA approvals for an ultra-rare hematologic malignancy using a single-arm study design validated through early regulatory dialogue
-
Complex Alzheimer's and Parkinson's programs maintained operational excellence despite challenging outcomes, preserving data integrity and sponsor relationships
The Path Forward
De-risking your neurology IND isn't about eliminating uncertainty, it's about managing it through foresight and collaboration. Early FDA engagement transforms potential roadblocks into navigable pathways, creating a foundation for transparent, science-driven development.
For neurology sponsors, the message is clear: invest in strategic regulatory planning early, and build the collaborative relationships that will sustain your program from first FDA meeting through global approval.
Ready to strengthen your neurology IND strategy? Download our comprehensive white paper "De-Risking the Neurology IND: Lessons from Early FDA Engagement" to learn how integrated regulatory and clinical expertise can accelerate your path to first-in-human success.
Learn More:
-
Trends in Oncology Regulation: FDA Draft Guidance on OS and Radiopharmaceuticals
-
From Clinical Strategy to Patient Impact: 5 Lessons from Cindy Henderson
-
Accelerate Your Oncology Therapy Breakthroughs with Veristat